top of page
Abstract Line Pattern

Waldenstrom Macroglobulinemia

Waldenstrom Macroglobulinemia

Phase 4 Observational Study of Zanubrutinib
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia.

Principal Investigator (PI)

Clinical Trials.gov ID

Key Eligibility

Protocol #

SPONSOR

BeiGene
bottom of page